Visceral adiposity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-20. Numbers and descriptions here follow the published literature rather than marketing material.
监管记录显示,特沙莫瑞林于 2010 年在美国首次获得批准,用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验,而非体重或瘦体重的普遍改善。后续出现了不同制剂版本,但其核心适应症保持一致。关于长期心血管结局和死亡率影响,现有证据仍不充分。
在临床研究之外,特沙莫瑞林常被讨论为生长激素分泌促进剂,但这一说法需要限定。它并不等同于生长激素本身,也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力,另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中,尚未形成统一结论。
特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年,美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
==== US reactions ==== The Soviet success raised a great deal of concern in the United States. For example, economist Bernard Baruch wrote in an open letter titled "The Lessons of Defeat" to the New York Herald Tribune: "While we devote our industrial and technological power to producing new model automobiles and more gadgets, the Soviet Union is conquering space. ... It is Russia, not the United States, who has had the imagination to hitch its wagon to the stars and the skill to reach for the moon and all but grasp it. America is worried. It should be." Eisenhower ordered project Vanguard to move up its timetable and launch its satellite much sooner than originally planned. The December 6, 1957 Project Vanguard launch failure occurred at Cape Canaveral Air Force Station in Florida. It was a monumental failure, exploding a few seconds after launch, and it became an international joke. The satellite appeared in newspapers under the names Flopnik, Stayputnik, Kaputnik, and Dudnik. In the United Nations, the Soviet delegate offered the US representative aid "under the Soviet program of technical assistance to backwards nations." Only in the wake of this very public failure did von Braun's Redstone team get the go-ahead to launch their Jupiter-C rocket as soon as they could. In Britain, the US's Western Cold War ally, the reaction was mixed: some celebrated the fact that the Soviets had reached space first, while others feared the destructive potential that military uses of spacecraft might bring.
Some of the earliest ancient human civilisations in South Asia originated from areas encompassing present-day Pakistan. The earliest known stone tools in the region, dating to the Lower Palaeolithic (~2 million years ago), were discovered in the Soan Valley of northern Pakistan. The Indus plain region, which covers most of the present-day Pakistan, was the site of several successive ancient cultures including the Neolithic (7000–4300 BCE) site of Mehrgarh, and the 5,000-year history of urban life in South Asia to the various sites of the Indus Valley Civilisation, including Mohenjo-daro and Harappa. Following the decline of the Indus Valley Civilisation, semi-nomadic Indo-European Aryans migrated into the Indian subcontinent around 2000 BCE, perhaps by way of the Khyber Pass. They fused with the indigenous Harappan culture of the Indus Valley, and elements of the pre-Aryan spiritual traditions were assimilated into the developing Vedic tradition. This cultural milieu shaped the Gandhara Civilisation, which flourished at the crossroads of India, Central Asia, and the Middle East, connecting trade routes and absorbing cultural influences from diverse civilisations. By the early Vedic period, parts of the Indus region in present-day Pakistan were populated by numerous tribes that were beginning to coalesce into chieftain-led clans and early kingdoms. During this period, the Vedas, the oldest scriptures of Hinduism, were composed.
According to The Hill, after the Navy's 4th Fleet Operation Southern Spear envisioned "deploying robotic surface vessels, small robotic interceptor boats and vertical take-off and landing robotic air vessels to the Southcom region", in November 2025, Hegseth formally unveiled the Joint Task Force Operation Southern Spear, "made up of ground, air and logistics troops, to 'synchronize and augment counter-narcotics efforts across the Western Hemisphere'." The campaign was formally named on 13 November 2025 by Hegseth on orders from Trump, bearing the same name as the operation announced by the Navy on 28 January 2025. The Joint Task Force headquarters are at Naval Station Mayport in Florida, with operations to begin later in November. The New York Times described the Chairman of the US Joint Chiefs of Staff, Dan Caine, as a "major architect" of the operation. On 6 August 2026, U.S. Southern Command announced the creation Joint Task Force Western Hemisphere (JTF-WHEM) which will replace Operation Southern Spear. It will be a unified command of the 18 partner nations of the Americas Counter Cartel Coalition (A3C). Marine Corps Maj. Gen. Kevin Jarrard will command the task force.
2,5-Diketopiperazine is an organic compound with the formula (NHCH2C(O))2. The compound features a six-membered ring containing two amide groups at opposite positions in the ring. It was first compound containing a peptide bond to be characterized by X-ray crystallography in 1938. It is the parent of a large class of 2,5-Diketopiperazines (2,5-DKPs) with the formula (NHCH2(R)C(O))2 (R = H, CH3, etc.). They are ubiquitous peptides in nature. They are often found in fermentation broths and yeast cultures as well as embedded in larger more complex architectures in a variety of natural products as well as several drugs. In addition, they are often produced as degradation products of polypeptides, especially in foods and beverages. They have also been found in extraterrestrial objects such as comets and asteroids.
==== Elimination ==== Gabapentin, pregabalin, Baclofen and phenibut are all eliminated renally in the urine. They all have relatively short elimination half-lives, with reported values of 5.0 to 7.0 hours, 6.3 hours, 2.0 to 5.0 hours and 5.3 hours, respectively. Similarly, the terminal half-life of gabapentin enacarbil IR (as active gabapentin) is short at approximately 4.5 to 6.5 hours. Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels. Similarly, pregabalin has been given 2 to 3 times per day in clinical studies. Phenibut, also, is taken 3 times per day. Conversely, gabapentin enacarbil is taken twice a day and gabapentin XR (brand name Gralise) is taken once a day.
Sources: en.wikipedia.org
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
At half-neutralization the ratio [A−]/[HA] = 1; since log(1) = 0, the pH at half-neutralization is numerically equal to pKa. Conversely, when pH = pKa, the concentration of HA is equal to the concentration of A−. The buffer region extends over the approximate range pKa ± 2. Buffering is weak outside the range pKa ± 1. At pH ≤ pKa − 2 the substance is said to be fully protonated and at pH ≥ pKa + 2 it is fully dissociated (deprotonated). If the pH is known, the ratio may be calculated. This ratio is independent of the analytical concentration of the acid. In water, measurable pKa values range from about −2 for a strong acid to about 12 for a very weak acid (or strong base). A buffer solution of a desired pH can be prepared as a mixture of a weak acid and its conjugate base. In practice, the mixture can be created by dissolving the acid in water, and adding the requisite amount of strong acid or base. When the pKa and analytical concentration of the acid are known, the extent of dissociation and pH of a solution of a monoprotic acid can be easily calculated using an ICE table.
==== Poland ==== The first Polish Taco Bell store was opened in 1993. Following an aggressive campaign of expansion, Taco Bell's efforts soon withered, and the chain withdrew from Poland shortly thereafter. In 2026, AmRest announced, that Taco Bell will return to the Polish market. The first new Taco Bell restaurant is expected to open in the fourth quarter of 2026, with additional locations to follow over time.
=== Anti-aging potential === Colostrinin affects the early stages of Vitamin D3-induced phenotypic (CD11b and CD14) and functional (phagocytic) differentiation/maturation of monocytes/macrophages. When Colostrinin was administered to the cells after treatment with Vitamin D3, no attenuation of the differentiation/maturation process of the HL-60 cells was observed. An in-vitro study completed in 2005 showed that Colostrinin can increase the lifespan of cells isolated from inbred mice predisposed to premature aging and death. A 2006 study published in the Journal of Experimental Therapeutics and Oncology indicated that Colostrin reduces the mutation frequency in the DNA of cells. Such DNA damage is implicated in the general process of aging. The study, which was performed in both hamster and human cells, looked at the effect of Colostrinin on the frequency of defined DNA mutations in these cells as they occur naturally and when induced by various known chemical or physical agents. In cells stressed oxidatively, Colostrinin reduced the frequency of mutation induced by reactive oxygen species (ROS) to nearly background levels in a dose-dependent manner. Likewise, Colostrinin reduced the frequency of mutation caused by two mutagenic agents, methyl methane sulfonate and mitomycin-C, the latter often used in cancer chemotherapy. Notably Colostrinin decreased UVA and UVB radiation induced mutation frequency. These damaging radiations are a natural part of sunlight.
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称,指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽,序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良,目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化,但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.